TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30350406

Group type: EXPERIMENTAL
Intervention: Integrated intervention combining health systems navigation and psychosocial counselling for early engagement of antiretroviral therapy (ART) and substance use treatment for PWID living with HIV.
Number of subjects: 1154
Study: 27793141

Group type: EXPERIMENTAL
Intervention: Multi-component, school-based, physical activity intervention
Number of subjects: 3124
Study: 25891551

Group type: EXPERIMENTAL
Intervention: Baseline T2 lesion volume
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Baseline measures of atrophy (BPV, GMV, NAWMV)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Decrease in SIENA (1%)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Decrease in brain volume SIENA (1%)
Number of subjects: 43
Study: 22873943

Group type: EXPERIMENTAL
Intervention: FlexTouch® (FT)
Number of subjects: 120
Study: 20514495

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 24
Study: 18727478

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Drugs only (Control)
Number of subjects: 216
Study: 15908299

Group type: EXPERIMENTAL
Intervention: Oral challenge tests with NSAIDs
Number of subjects: 260
Study: 12766095

Group type: EXPERIMENTAL
Intervention: Monthly remunerated routine chiropodist care (n = 47)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Chiropodist care per protocol (n = 47)
Number of subjects: 91
Study: 10819735

Group type: EXPERIMENTAL
Intervention: Teaching interventions during home care
Number of subjects: 148
Study: 8844033

Group type: EXPERIMENTAL
Intervention: Diazepam loading dose therapy (40 to 210 mg, mean 86.9 ± 47.2 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional therapy (diazepam and other psychotropic drugs in divided doses)
Number of subjects: 96
Study: 1906074

Group type: EXPERIMENTAL
Intervention: Lipid-based feeding
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Glucose-based feeding
Number of subjects: 44

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 44
Study: 6345501

Group type: EXPERIMENTAL
Intervention: Propranolol (up to 120 mg per day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31801742

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 422
Study: 29272029

Group type: EXPERIMENTAL
Intervention: Telephone call from a nurse using a scripted questionnaire
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Satisfaction survey only (Control)
Number of subjects: 2000
Study: 26610165

Group type: EXPERIMENTAL
Intervention: Placebo cream with suggestion of reduced skin reaction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control session (no treatment)
Number of subjects: 48
Study: 25325498

Group type: EXPERIMENTAL
Intervention: Armodafinil (150 mg)
Number of subjects: 20
Study: 22811410

Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/m² Days 1 and 29 and 5-fluorouracil 700 mg/m² Days 1-5 and 29-33 with radiotherapy 60 Gy/30 fr/7 weeks (arm A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cisplatin 7 mg/m² Days 1-5, 8-12, 29-33 and 36-40 and 5-fluorouracil 250 mg/m² Days 1-14 and 29-42 with the same radiotherapy (arm B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 91
Study: 20099948

Group type: EXPERIMENTAL
Intervention: Precaution Adoption Model (PAM)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Behavioral Action Model (BAM)
Number of subjects: 133
Study: 19069889

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally, 2 times at 6 h intervals)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Oxytocin (6 mu min(‐1) infusion)
Number of subjects: 110
Study: 16245968

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/mL for 5 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no mitomycin C)
Number of subjects: 14
Study: 12081834

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 21
Study: 9861326

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 8583134

Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa‐2b thrice weekly for 6 months
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 5 million units of interferon alfa‐2b thrice weekly for 6 months
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa‐2b thrice weekly for 2 years
Number of subjects: 230

Group type: COMPARATOR
Intervention: 6 months treatment
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 2 years treatment
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Absence of cirrhosis
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Presence of cirrhosis
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Injecting drug use
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Sporadic cases
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 2 years treatment vs 6 months treatment
Number of subjects: 230
Study: 2164415

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7267673

Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg twice daily
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Cephalexin 1 g twice daily
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Cephalexin (both dosages)
Number of subjects: 752
Study: 30513252

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐HB‐PRPT primary and booster vaccination with birth dose of HB
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP‐IPV‐HB‐PRPT primary and booster vaccination without birth dose of HB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP‐HB‐IPV//PRPT primary and booster vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐HB‐PRPT or DTaP‐HB‐IPV//PRPT booster
Number of subjects: 0
Study: 28395375

Group type: EXPERIMENTAL
Intervention: Four-week rehabilitation program
Number of subjects: 42
Study: 25720600

Group type: EXPERIMENTAL
Intervention: Intravenous Insulin Infusion (IV-I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Subcutaneous Insulin (SC-I)
Number of subjects: 45
Study: 24393424

Group type: EXPERIMENTAL
Intervention: Presepsin (sCD14‐ST) measured on day 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measured on day 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presepsin levels over time
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Procalcitonin levels over time
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presepsin as a predictor of mortality
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prognostic accuracy of Presepsin vs PCT
Number of subjects: 100
Study: 21609254

Group type: EXPERIMENTAL
Intervention: 1% alendronate gel
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 17
Study: 19546271

Group type: EXPERIMENTAL
Intervention: Powered air-purifying respirators
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Conventional respirators
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 14
Study: 17309967

Group type: EXPERIMENTAL
Intervention: Italian Cleveland Global Quality of Life (CGQL) instrument
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Padova Inflammatory Bowel Disease Quality of Life instrument
Number of subjects: 40
Study: 17310813

Group type: EXPERIMENTAL
Intervention: Didanosine (ddl)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 14597353

Group type: EXPERIMENTAL
Intervention: Single fraction of 8 Gy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Six fractions of 4 Gy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Axial cortical involvement >30 mm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Axial cortical involvement < or =30 mm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Higher total dose irradiation or prophylactic surgery
Number of subjects: 102
Study: 10650537

Group type: EXPERIMENTAL
Intervention: Team-building intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cohesion measures (Individual attractions to the group‐social, Group integration‐social, Group integration‐task)
Number of subjects: 0
Study: 8966062

Group type: EXPERIMENTAL
Intervention: During attack (I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: After regression of symptoms (II)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 25
Study: 1802656

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) given at a dose of 10 ml/kg daily for the first three days of life
Number of subjects: 38

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 38
Study: 6363680

Group type: EXPERIMENTAL
Intervention: Behavioural techniques to reduce swallowing rate
Number of subjects: 12
Study: 30814777

Group type: EXPERIMENTAL
Intervention: 6-week home-based exercise program before TKA surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no prehabilitation)
Number of subjects: 20
Study: 28143564

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered within 3 hours of injury
Number of subjects: 20211

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered after 3 hours of injury
Number of subjects: 20211

Group type: EXPERIMENTAL
Intervention: Subgroup analyses for early TXA treatment
Number of subjects: 20211

Group type: EXPERIMENTAL
Intervention: Subgroup analyses for late TXA treatment
Number of subjects: 20211

Group type: EXPERIMENTAL
Intervention: Multivariable analysis of TXA effect
Number of subjects: 20211
Study: 26060823

Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR
Number of subjects: 1834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1834
Study: 23022602

Group type: EXPERIMENTAL
Intervention: High protein yogurt snack (24 g protein)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate protein yogurt snack (14 g protein)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low protein yogurt snack (5 g protein)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No snack (NS)
Number of subjects: 15
Study: 20671652

Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin, titrated to maintain LDL cholesterol <100 mg/dL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin
Number of subjects: 100
Study: 17989103

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at 2 g/day for 6 months along with prednisolone at 0.5 mg/kg/day for 2-3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional therapy: prednisolone 1 mg/kg/day for 3-6 months for FSGS and alternating monthly cycles of steroids and cyclophosphamide for 6 months for MN
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study: 15694878

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.08 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 12886119

Group type: EXPERIMENTAL
Intervention: Natural environment intervention (120 minutes of exposure per week)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nonintervention group (control)
Number of subjects: 157
Study: 10540048

Group type: COMPARATOR
Intervention: Alpha2b‐interferon alone (3‐8 MU, three times weekly for 6 months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination therapy (Alpha2b‐interferon + ketoprofen 200 mg/day five times weekly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alpha2b‐interferon alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 50
Study: 8551786

Group type: EXPERIMENTAL
Intervention: Nafamostat (2 mg/kg per hour) during cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no nafamostat)
Number of subjects: 20
Study: 1678039

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 876

Group type: COMPARATOR
Intervention: Chest physiotherapy
Number of subjects: 876
Study: 6410730

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 46
Study: 31615771

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Interleukin 6
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group
Number of subjects: 690

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 690
Study: 28202032

Group type: EXPERIMENTAL
Intervention: Tele-based health coaching intervention (monthly individual health coaching by telephone for 12 months)
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Routine social and health care (control group)
Number of subjects: 1570
Study: 23489282

Group type: EXPERIMENTAL
Intervention: Metformin (2g daily for three months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No metformin (control group)
Number of subjects: 40
Study: 24206588

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) monotherapy
Number of subjects: 143
Study: 20581719

Group type: EXPERIMENTAL
Intervention: Aerobic training (educational program + breathing exercises + aerobic training)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (educational program + breathing exercises)
Number of subjects: 68
Study: 19161878

Group type: EXPERIMENTAL
Intervention: EM-PCI (Export Medtronic thrombectomy device)
Number of subjects: 175
Study: 17191233

Group type: EXPERIMENTAL
Intervention: Expectation-maximization (EM) algorithm with mixture of multivariate Gaussians (MoMG) for analyzing brain perfusion from DSC MR images
Number of subjects: 1

Group type: COMPARATOR
Intervention: Results from normal subjects
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Results from a patient with CAVM
Number of subjects: 1
Study: 15609766

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 42
Study: 10696827

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study: 9350366

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.017 mg.kg‐1) with sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.017 mg.kg‐1) with isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.017 mg.kg‐1) with enflurane
Number of subjects: 30
Study: 1486156

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg q.d.s.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 600 mg b.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 20
Study: 4040699

Group type: EXPERIMENTAL
Intervention: Functioning Uristop device
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-functioning device (Control)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (Functioning and Non-functioning devices)
Number of subjects: 53
Study: 31779697

Group type: EXPERIMENTAL
Intervention: PG102P 1.5 g/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27192352

Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSM), n = 119
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard partial mastectomy (no shave), n = 116
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSM)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard partial mastectomy (no shave)
Number of subjects: 235
Study: 26407852

Group type: EXPERIMENTAL
Intervention: Daily vaginal progesterone until the 37th week of gestation or delivery
Number of subjects: 254

Group type: COMPARATOR
Intervention: Cervical pessary until the 37th week of gestation or delivery
Number of subjects: 254
Study: 23435698

Group type: EXPERIMENTAL
Intervention: Cash transfer intervention conditional on school attendance
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 21362524

Group type: EXPERIMENTAL
Intervention: Nesiritide (0.01 μg kg(‐1) min(‐1) ± bolus)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nitroglycerin (maximally tolerated doses by standard protocol)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nesiritide and Nitroglycerin
Number of subjects: 89
Study: 19625139

Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-radiotherapy (non-RT)
Number of subjects: 0
Study: 17179242

Group type: EXPERIMENTAL
Intervention: Intraoperative cerebral regional oxygen saturation (rSO2) monitoring with active display and treatment intervention protocol (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Blinded rSO2 monitoring (n = 100)
Number of subjects: 200
Study: 15369567

Group type: EXPERIMENTAL
Intervention: Outpatient chemical dependency treatment
Number of subjects: 925
Study: 14622826

Group type: EXPERIMENTAL
Intervention: Cognitive/emotional stress (20-minute Stroop test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation (tape)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (neutral video)
Number of subjects: 0
Study: 10444054

Group type: EXPERIMENTAL
Intervention: Preserved saline solutions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Saline preserved with ethylene‐diamine‐tetraacetic acid (EDTA) in conjunction with sorbic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unpreserved saline (previously published study)
Number of subjects: 40
Study: 8561488

Group type: EXPERIMENTAL
Intervention: Low-fat test dish presented as low-fat
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-fat test dish
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-fat test dish presented as high-fat
Number of subjects: 16
Study: 2190935

Group type: EXPERIMENTAL
Intervention: Anatomical reduction (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sarmiento osteotomy and valgus reduction (Group 2)
Number of subjects: 100
Study: 380434

Group type: EXPERIMENTAL
Intervention: True hemodialysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham hemodialysis
Number of subjects: 7
Study: 31142104

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (A+R)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 52
Study: 28400091

Group type: EXPERIMENTAL
Intervention: AA-MF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GMP-MF
Number of subjects: 18
Study: 25378365

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (contacted by a trained nurse navigator by telephone to discuss colorectal cancer screening)
Number of subjects: 5240

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 5240
Study: 27276758

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) - 12 weeks of aerobic and resistance training for 60 minutes, three sessions per week.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG) - no specific intervention mentioned.
Number of subjects: 32
Study: 21828944

Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-MGuard stent
Number of subjects: 46
Study: 19842973

Group type: EXPERIMENTAL
Intervention: ABC-3TC
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: TDF-FTC
Number of subjects: 357
Study: 16723320

Group type: EXPERIMENTAL
Intervention: Counting in circle arrays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counting in curved lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counting strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Error types in counting
Number of subjects: 0
Study: 14607566

Group type: EXPERIMENTAL
Intervention: Ketoconazole (50 mg every 48 hours) with hMG
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo with hMG
Number of subjects: 109
Study: 10791445

Group type: EXPERIMENTAL
Intervention: Fluconazole oral suspension
Number of subjects: 305

Group type: COMPARATOR
Intervention: Amphotericin B oral suspension
Number of subjects: 305
Study: 8877335

Group type: EXPERIMENTAL
Intervention: Ulfon Lyoc in lyophilised tablet form (group 1; n = 40)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ulfon suspension (group 2; n = 39)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ulfon Lyoc and Ulfon suspension
Number of subjects: 79
Study: 1921400

Group type: EXPERIMENTAL
Intervention: R1 gastrectomy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: R2 gastrectomy
Number of subjects: 93
Study: 6356322

Group type: EXPERIMENTAL
Intervention: Sucralfate 500 mg before breakfast, lunch, supper and 1000 mg on retiring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3083505

Group type: EXPERIMENTAL
Intervention: Auranofin (6 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Penicillamine (go slow and low regime)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auranofin and Penicillamine
Number of subjects: 40